Targeting the CAV2/PACT/PKR axis may therefore represent a promising therapeutic strategy to potentiate the efficacy of EGFR-targeted therapy in patients with HNSCC. The gene discussed is CAV2; the disease is head and neck squamous cell carcinoma.